Piramal Pharma Solutions Partners with IntoCell to Enhance Bioconjugate Capabilities

Piramal Pharma Solutions has announced a partnership with IntoCell to expand its offerings in bioconjugates and bolster its position in the market. This collaboration integrates IntoCell's proprietary drug-linker technologies with Piramal's extensive expertise in antibody-drug conjugates (ADC) development. The new agreement enhances Piramal's ADCelerate™ program, facilitating quicker development and manufacturing processes.

Through this non-binding agreement, IntoCell will license its drug-linker technologies to Piramal's clients, while Piramal will perform contract research, development, and manufacturing services. This partnership is expected to streamline routes from concept to clinic, offering a broader range of payload-linkers and shorter development times.

The CEOs of both companies expressed enthusiasm for the mutual benefits anticipated through this collaboration. By combining their technological strengths, they aim to set new standards in ADC development and benefit patients globally.